Ligand Pharma (LGND) Tops Q3 EPS by 8c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $287.59 -1.43%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.69, $0.08 better than the analyst estimate of $0.61. Revenue for the quarter came in at $33.38 million versus the consensus estimate of $30.91 million.
GUIDANCE:
Ligand Pharma sees FY2017 revenue of $134-136 million, versus the consensus of $134.5 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
